Mainz Biomed shares rise 10.32% premarket after showcasing cancer detection solutions at MEDICA 2025.

Mainz Biomed surged 10.32% in premarket trading following the announcement that the company will showcase its innovative cancer detection solutions at MEDICA 2025. This event highlights the firm’s progress in advancing its colorectal and pancreatic cancer screening technologies, aligning with recent commercial milestones such as the Swiss and UK launches of ColoAlert. While prior news, including financial losses and partnership updates, had historically pressured the stock, the premarket rally suggests renewed investor optimism tied to the visibility of the company’s pipeline at a major industry conference. The positive momentum contrasts with earlier bearish reports, reflecting confidence in Mainz Biomed’s ability to translate research into marketable solutions.